GeNeuro touts a mixed set of extension data in a shot at salvaging their failed mid-stage MS drug
Geneva-based GeNeuro managed to earn a spike in its share price after touting a distinctly mixed set of Phase IIb extension data for their failed multiple sclerosis drug temelimab.
Bullishly encouraging in their look at whether the drug could influence disease progression, the trial failed to hit statistical significance for several key endpoints, including a lower probability for a confirmed 12-week worsening in disability relative to the control group, where the p-value for the high dose hit 0.34. The p-value for the reduction of brain atrophy in the cortex — a biomarker for the disease — also fell short, at 0.058, with atrophy in the thalamus crossing the line at a positive 0.038.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.